LIMA project will be based on following 5 technology pillars:

  1. A robust method to measure and genomically analyze ct-DNA for tumor-driving mutations, which can be measured in a quantitative manner allowing therapy response prediction and monitoring.
  2. A workflow for Circulating Tumor Cell isolation and computational model-based quantitative signal pathway analysis on single CTC mRNA expression levels. This allows for assessment of tumor heterogeneity in pathway activity (to relate back to tumor heterogeneity), targeted therapy response prediction and monitoring.
  3. Correlation of computational, model-based cancer biology assessment from tissue samples before and after neoadjuvant treatment and from liquid biopsies with MR imaging features.
  4. Advance in MR imaging to better probe and image the cancer and its microenvironment.
  5. Clinical analysis, correlating liquid biopsy/imaging –based results to clinical outcome, that is the response to neoadjuvant therapy in breast cancer and rectal cancer patients.